The Px Wire centerspread from April-June 2013 Volume 6, No. 2 showcases the ARV-based HIV prevention pipeline from pre-clinical research to implementation projects.
ARV-Based Prevention Research and Development Product Pipeline
Achieving the End
Recent breakthroughs in HIV prevention research have created unprecedented opportunities to curb new HIV infections, save lives and set the world on a path towards eliminating HIV transmission.
Non-Surgical Devices for VMMC
Pictured here, from AVAC Report 2012, is the PrePex device and Shang Ring, two non-surgical devices in development for VMMC.
Plans and Missing Pieces in PrEP Demonstration Projects: USA
This infographic from AVAC Report 2012 identifies the design and key questions for ongoing or planned PrEP demonstration projects in the US.
People Not Receiving Antiretroviral and Treatment U=U and Services in One Year through Bilateral FY 2013 Sequestration
This graphic from AVAC Report 2012 illustrates the potential effects of US federal budget sequestration on HIV prevention and Treatment U=U implementation in 2013.
Follow-on trials based on RV144: Strategy includes development and research tracks
This graphic from AVAC Report 2012 shows several planned vaccine trials building on the results of the RV144 AIDS vaccine trial.
AVAC Playbook 2012-2013: Progress toward global goals
AVAC first published its Playbook of global goals for ending AIDS in late 2011. This infographic from the AVAC Report 2012 builds on the objectives from 2011 and identifies five priorities for action in 2013.
Defining Combination Prevention: Ongoing trials in sub-Saharan Africa
Stepping Up the Pace: VMMC accelerates in priority countries
As this graphic from AVAC Report 2012 illustrates, the pace of implementation of VMMC for HIV prevention has increased dramatically since 2010 in priority countries.
HIV Prevention Research: Defining moments since 2010
Published in AVAC Report 2011, this timeline shows the HIV prevention scientific breakthroughs from July 2010 to Nov 2011, including the CAPRISA 004, iPrEx and Partners PrEP trials.